European Journal of Medicinal Chemistry

, volume 257 , pages 115491

The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022

Xiaojuan Pang ¹

Wei Xu ²

Liu Yang ¹

Li Hua ^{1, 2}

Le-zhen Chen ¹

Hide authors affiliations Show authors affiliations: 2 affiliations

Wuya College of Innovation, Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, 110016, China |

Institute of Structural Pharmacology & TCM Chemical Biology, College of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou, 350122, China |

Publication type: Journal Article

Publication date: 2023-09-01

Elsevier

European Journal of Medicinal Chemistry

scimago Q1

wos Q1

SJR: 1.142

CiteScore: 11.3

Impact factor: 5.9

ISSN: 02235234, 17683254

DOI: 10.1016/j.ejmech.2023.115491

Copy DOI

PubMed ID: 37244162

Organic Chemistry

Drug Discovery

General Medicine

Pharmacology

Abstract

The novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide. The main protease (Mpro) of SARS-CoV-2 plays a central role in viral replication and transcription and represents an attractive drug target for fighting COVID-19. Many SARS-CoV-2 Mpro inhibitors have been reported, including covalent and noncovalent inhibitors. The SARS-CoV-2 Mpro inhibitor PF-07321332 (Nirmatrelvir) designed by Pfizer has been put on the market. This paper briefly introduces the structural characteristics of SARS-CoV-2 Mpro and summarizes the research progress of SARS-CoV-2 Mpro inhibitors from the aspects of drug repurposing and drug design. These information will provide a basis for the drug development of treating the infection of SARS-CoV-2 and even other coronaviruses in the future.

Found

1 citation

Yarovaya Olga

PhD in Chemistry

118 publications, 1 842 citations, 14 reviews

h-index: 23

N.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry of the Siberian Branch of the Russian Academy of Sciences

1 citation

Baev Dmitry

PhD in Biological/biomedical sciences

69 publications, 986 citations

h-index: 19

N.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry of the Siberian Branch of the Russian Academy of Sciences

1 citation

Chirkova Varvara

24 publications, 132 citations

h-index: 6

Altai State University

1 citation

Belenkaya Svetlana

PhD in Biological/biomedical sciences

39 publications, 269 citations

h-index: 9

State Research Center of Virology and Biotechnology VECTOR

N.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry of the Siberian Branch of the Russian Academy of Sciences

1 citation

Luzina Olga

DSc in Chemistry

105 publications, 1 288 citations, 22 reviews

h-index: 21

N.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry of the Siberian Branch of the Russian Academy of Sciences

Research interests

Chemistry of natural compounds

Medicinal Chemistry

Organic Chemistry

1 citation

Filimonov Aleksandr

25 publications, 210 citations

h-index: 8

N.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry of the Siberian Branch of the Russian Academy of Sciences

1 citation

Lider Elizaveta

🥼 🤝

PhD in Chemistry

67 publications, 642 citations

h-index: 14

Nikolaev Institute of Inorganic Chemistry of the Siberian Branch of the Russian Academy of Sciences

Novosibirsk State University

Top-30

Journals

	1 2 3 4 5 6
European Journal of Medicinal Chemistry	European Journal of Medicinal Chemistry, 6, 8% European Journal of Medicinal Chemistry 6 publications, 8%
ACS Medicinal Chemistry Letters	ACS Medicinal Chemistry Letters, 3, 4% ACS Medicinal Chemistry Letters 3 publications, 4%
Bioorganic Chemistry	Bioorganic Chemistry, 3, 4% Bioorganic Chemistry 3 publications, 4%
Frontiers in Pharmacology	Frontiers in Pharmacology, 3, 4% Frontiers in Pharmacology 3 publications, 4%
Journal of Molecular Structure	Journal of Molecular Structure, 2, 2.67% Journal of Molecular Structure 2 publications, 2.67%
Biochemical and Biophysical Research Communications	Biochemical and Biophysical Research Communications, 2, 2.67% Biochemical and Biophysical Research Communications 2 publications, 2.67%
International Journal of Molecular Sciences	International Journal of Molecular Sciences, 2, 2.67% International Journal of Molecular Sciences 2 publications, 2.67%
RSC Medicinal Chemistry	RSC Medicinal Chemistry, 2, 2.67% RSC Medicinal Chemistry 2 publications, 2.67%
Viruses	Viruses, 2, 2.67% Viruses 2 publications, 2.67%
International Journal of Biological Macromolecules	International Journal of Biological Macromolecules, 2, 2.67% International Journal of Biological Macromolecules 2 publications, 2.67%
Nutrients	Nutrients, 1, 1.33% Nutrients 1 publication, 1.33%
Acta Pharmaceutica Sinica B	Acta Pharmaceutica Sinica B, 1, 1.33% Acta Pharmaceutica Sinica B 1 publication, 1.33%
Antimicrobial Agents and Chemotherapy	Antimicrobial Agents and Chemotherapy, 1, 1.33% Antimicrobial Agents and Chemotherapy 1 publication, 1.33%
Future Virology	Future Virology, 1, 1.33% Future Virology 1 publication, 1.33%
Briefings in Bioinformatics	Briefings in Bioinformatics, 1, 1.33% Briefings in Bioinformatics 1 publication, 1.33%
Acta Crystallographica Section D: Structural Biology	Acta Crystallographica Section D: Structural Biology, 1, 1.33% Acta Crystallographica Section D: Structural Biology 1 publication, 1.33%
Computational Biology and Chemistry	Computational Biology and Chemistry, 1, 1.33% Computational Biology and Chemistry 1 publication, 1.33%
Chemistry and Biodiversity	Chemistry and Biodiversity, 1, 1.33% Chemistry and Biodiversity 1 publication, 1.33%
Veterinary Quarterly	Veterinary Quarterly, 1, 1.33% Veterinary Quarterly 1 publication, 1.33%
The Analyst	The Analyst, 1, 1.33% The Analyst 1 publication, 1.33%
COVID	COVID, 1, 1.33% COVID 1 publication, 1.33%
Drugs	Drugs, 1, 1.33% Drugs 1 publication, 1.33%
Journal of Enzyme Inhibition and Medicinal Chemistry	Journal of Enzyme Inhibition and Medicinal Chemistry, 1, 1.33% Journal of Enzyme Inhibition and Medicinal Chemistry 1 publication, 1.33%
Results in Chemistry	Results in Chemistry, 1, 1.33% Results in Chemistry 1 publication, 1.33%
Expert Opinion on Biological Therapy	Expert Opinion on Biological Therapy, 1, 1.33% Expert Opinion on Biological Therapy 1 publication, 1.33%
ACS Omega	ACS Omega, 1, 1.33% ACS Omega 1 publication, 1.33%
Drug Discovery Today	Drug Discovery Today, 1, 1.33% Drug Discovery Today 1 publication, 1.33%
Structure	Structure, 1, 1.33% Structure 1 publication, 1.33%
Frontiers in Molecular Biosciences	Frontiers in Molecular Biosciences, 1, 1.33% Frontiers in Molecular Biosciences 1 publication, 1.33%
	1 2 3 4 5 6

Publishers

	5 10 15 20 25 30 35
Elsevier	Elsevier, 31, 41.33% Elsevier 31 publications, 41.33%
MDPI	MDPI, 9, 12% MDPI 9 publications, 12%
American Chemical Society (ACS)	American Chemical Society (ACS), 6, 8% American Chemical Society (ACS) 6 publications, 8%
Taylor & Francis	Taylor & Francis, 5, 6.67% Taylor & Francis 5 publications, 6.67%
Royal Society of Chemistry (RSC)	Royal Society of Chemistry (RSC), 4, 5.33% Royal Society of Chemistry (RSC) 4 publications, 5.33%
Frontiers Media S.A.	Frontiers Media S.A., 4, 5.33% Frontiers Media S.A. 4 publications, 5.33%
Springer Nature	Springer Nature, 3, 4% Springer Nature 3 publications, 4%
American Society for Microbiology	American Society for Microbiology, 2, 2.67% American Society for Microbiology 2 publications, 2.67%
Wiley	Wiley, 2, 2.67% Wiley 2 publications, 2.67%
Oxford University Press	Oxford University Press, 1, 1.33% Oxford University Press 1 publication, 1.33%
International Union of Crystallography (IUCr)	International Union of Crystallography (IUCr), 1, 1.33% International Union of Crystallography (IUCr) 1 publication, 1.33%
OOO Zhurnal "Mendeleevskie Soobshcheniya"	OOO Zhurnal "Mendeleevskie Soobshcheniya", 1, 1.33% OOO Zhurnal "Mendeleevskie Soobshcheniya" 1 publication, 1.33%
Public Library of Science (PLoS)	Public Library of Science (PLoS), 1, 1.33% Public Library of Science (PLoS) 1 publication, 1.33%
SAGE	SAGE, 1, 1.33% SAGE 1 publication, 1.33%
Bentham Science Publishers Ltd.	Bentham Science Publishers Ltd., 1, 1.33% Bentham Science Publishers Ltd. 1 publication, 1.33%
Walter de Gruyter	Walter de Gruyter, 1, 1.33% Walter de Gruyter 1 publication, 1.33%
	5 10 15 20 25 30 35

We do not take into account publications without a DOI.
Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.

Metrics

Cite this

GOST |

Cite this

GOST Copy

Pang X. et al. The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022 // European Journal of Medicinal Chemistry. 2023. Vol. 257. p. 115491.

GOST all authors (up to 50) Copy

Pang X., Xu W., Yang L., Hua L., Chen L. The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022 // European Journal of Medicinal Chemistry. 2023. Vol. 257. p. 115491.

RIS |

Cite this

RIS Copy

TY - JOUR

DO - 10.1016/j.ejmech.2023.115491

UR - https://doi.org/10.1016/j.ejmech.2023.115491

TI - The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022

T2 - European Journal of Medicinal Chemistry

AU - Pang, Xiaojuan

AU - Xu, Wei

AU - Yang, Liu

AU - Hua, Li

AU - Chen, Le-zhen

PY - 2023

DA - 2023/09/01

PB - Elsevier

SP - 115491

VL - 257

PMID - 37244162

SN - 0223-5234

SN - 1768-3254

ER -

BibTex

Cite this

BibTex (up to 50 authors) Copy

@article{2023_Pang,

author = {Xiaojuan Pang and Wei Xu and Liu Yang and Li Hua and Le-zhen Chen},

title = {The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022},

journal = {European Journal of Medicinal Chemistry},

year = {2023},

volume = {257},

publisher = {Elsevier},

month = {sep},

url = {https://doi.org/10.1016/j.ejmech.2023.115491},

pages = {115491},

doi = {10.1016/j.ejmech.2023.115491}

}

Publisher

Elsevier

Journal

European Journal of Medicinal Chemistry

scimago Q1

wos Q1

SJR

1.142

CiteScore

11.3

Impact factor

5.9

ISSN

02235234 (Print)

17683254 (Electronic)

Profiles

Lixia Xia Chen